| Q47303095 | Activated HGF-c-Met Axis in Head and Neck Cancer |
| Q42456210 | Association of the human astrocyte elevated gene-1 promoter variants with susceptibility to hepatocellular carcinoma |
| Q26751332 | Biomarker development in MET-targeted therapy |
| Q37352553 | CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer |
| Q35501246 | Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges |
| Q42261011 | Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma |
| Q35970966 | Distinct pathways of genomic progression to benign and malignant tumors of the liver. |
| Q35874388 | Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling |
| Q34782774 | Drug development of MET inhibitors: targeting oncogene addiction and expedience |
| Q36519010 | Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
| Q35532215 | EPMA position paper in cancer: current overview and future perspectives |
| Q33644158 | Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. |
| Q36178311 | Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis |
| Q47910739 | Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma. |
| Q36957055 | Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53 |
| Q45883662 | Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy |
| Q43148137 | Liver stem cells and molecular signaling pathways in hepatocellular carcinoma |
| Q55003371 | Measurement of Serum and Hepatic Eicosanoids by Liquid Chromatography Tandem-Mass Spectrometry (LC-MS/MS) in a Mouse Model of Hepatocellular Carcinoma (HCC) with Delivery of c-Met and Activated β-Catenin by Hepatocyte Hydrodynamic Injection. |
| Q41753530 | Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients |
| Q78357688 | Molecular pathogenesis of human hepatocellular carcinoma |
| Q38151670 | Molecular targeted therapy for hepatocellular carcinoma: current and future |
| Q66679281 | New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies |
| Q34964958 | Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors |
| Q34347580 | Principles of liver regeneration and growth homeostasis |
| Q34412775 | Progranulin A-mediated MET signaling is essential for liver morphogenesis in zebrafish. |
| Q35810123 | Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature |
| Q34632043 | Scatter-factor and semaphorin receptors: cell signalling for invasive growth |
| Q88803055 | Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis |
| Q40676271 | Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells |
| Q34062598 | Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis |
| Q36766188 | Targeting the HGF-cMET Axis in Hepatocellular Carcinoma |
| Q36093497 | Targeting the HGF/c-MET pathway in hepatocellular carcinoma |
| Q39270291 | Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma |
| Q89967621 | The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma |
| Q40500532 | The Met protooncogene is a transcriptional target of NF kappaB: implications for cell survival |
| Q34668320 | The prognostic molecular markers in hepatocellular carcinoma |
| Q41339988 | The role of autophagy in hepatocellular carcinoma: friend or foe. |
| Q37773788 | The role of signaling pathways in the development and treatment of hepatocellular carcinoma |
| Q80554209 | [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology] |
| Q38923535 | c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma |
| Q33886974 | c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer |